Lexicon Pharmaceuticals, Inc. (LXRX) announced on Monday the appointment of Mike Exton as the new Chief Executive Officer and Director of the company. Exton takes over from Lonnel Coats, who retired effective July 7, 2024, as previously announced. Prior to this, Exton held the role of Global Cardiometabolic Therapeutic Head at Novartis.
"I am confident that Mike is the right person to serve as Lexicon's next CEO at this critical juncture for the company," said Ray Debbane, Chairman of Lexicon's Board of Directors.
Commenting on his new role, Dr. Exton said, "I am excited and honored to be appointed Lexicon's new Chief Executive Officer. I am impressed with Lexicon's current assets and pipeline, and I look forward to leading this talented group of employees as we work towards our near-term objectives to create future value."
Additionally, Jeff Wade has been named President and Chief Operating Officer. Wade has been serving as Lexicon's President and Chief Financial Officer since October 2021, and has previously held various positions in finance, corporate development, administration, and legal leadership since joining the company.
